Last reviewed · How we verify
Fuji Yakuhin Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| FYU-981 | FYU-981 | phase 3 | ||||
| FFI-1010 | FFI-1010 | phase 3 | BTK inhibitor | BTK | Oncology |
Therapeutic area mix
- Diabetes · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Pfizer · 2 shared drug classes
- AstraZeneca · 2 shared drug classes
- Eli Lilly and Company · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- Pierre Fabre Medicament · 2 shared drug classes
- AceLink Therapeutics, Inc. · 1 shared drug class
- Abbott · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Fuji Yakuhin Co., Ltd.:
- Fuji Yakuhin Co., Ltd. pipeline updates — RSS
- Fuji Yakuhin Co., Ltd. pipeline updates — Atom
- Fuji Yakuhin Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Fuji Yakuhin Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fuji-yakuhin-co-ltd. Accessed 2026-05-17.